Stock Research for BIOAF

BIOAF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BIOAF Stock Chart & Research Data

The BIOAF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIOAF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BIOAF Due diligence Resources & Stock Charts

The BIOAF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIOAF Detailed Price Forecast - CNN Money CNN View BIOAF Detailed Summary - Google Finance
Yahoo View BIOAF Detailed Summary - Yahoo! Finance Zacks View BIOAF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BIOAF Trends & Analysis - Trade-Ideas Barrons View BIOAF Major Holders - Barrons
NASDAQ View BIOAF Call Transcripts - NASDAQ Seeking View BIOAF Breaking News & Analysis - Seeking Alpha
Spotlight View BIOAF Annual Report - CompanySpotlight.com OTC Report View BIOAF OTC Short Report - OTCShortReport.com
TradeKing View BIOAF Fundamentals - TradeKing Charts View BIOAF SEC Filings - Bar Chart
WSJ View Historical Prices for BIOAF - The WSJ Morningstar View Performance/Total Return for BIOAF - Morningstar
MarketWatch View the Analyst Estimates for BIOAF - MarketWatch CNBC View the Earnings History for BIOAF - CNBC
StockMarketWatch View the BIOAF Earnings - StockMarketWatch MacroAxis View BIOAF Buy or Sell Recommendations - MacroAxis
Bullish View the BIOAF Bullish Patterns - American Bulls Short Pains View BIOAF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BIOAF Stock Mentions - StockTwits PennyStocks View BIOAF Stock Mentions - PennyStockTweets
Twitter View BIOAF Stock Mentions - Twitter Invest Hub View BIOAF Investment Forum News - Investor Hub
Yahoo View BIOAF Stock Mentions - Yahoo! Message Board Seeking Alpha View BIOAF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BIOAF - SECform4.com Insider Cow View Insider Transactions for BIOAF - Insider Cow
CNBC View BIOAF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIOAF - OTC Markets
Yahoo View Insider Transactions for BIOAF - Yahoo! Finance NASDAQ View Institutional Holdings for BIOAF - NASDAQ


Stock Charts

FinViz View BIOAF Stock Insight & Charts - FinViz.com StockCharts View BIOAF Investment Charts - StockCharts.com
BarChart View BIOAF Stock Overview & Charts - BarChart Trading View View BIOAF User Generated Charts - Trading View




Latest Financial News for BIOAF


Bioasis Announces Non-Brokered Private Placement
Posted on Monday July 16, 2018

OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) for the treatment of CNS disorders, today announced that it intends to pursue a non-brokered private placement of units (the "Units") at a price of C$0.552 per Unit, for aggregate gross proceeds of up to C$3 million.


Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
Posted on Wednesday July 11, 2018

OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced a strategic collaboration to partner on the development and validation of bioanalytical methods to support and advance the xB3 TM-001 program, Bioasis’ lead candidate to treat HER2+ brain cancer, to investigational new drug (IND) submission and into the clinic. The development and validation of bioanalytical methods are critical to ensuring the highest quality data to support regulatory approval of the IND and clinical pharmacokinetic data that will allow the Company to define the clinical dose for the program to ensure maximum therapeutic benefit for patients in Phase 1 and beyond.


Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
Posted on Tuesday June 26, 2018

BIOASIS TECHNOLOGIES INC. , a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its fourth quarter and annual audited consolidated financial statements ...


BiOasis: Fiscal 4Q Earnings Snapshot
Posted on Tuesday June 26, 2018

On a per-share basis, the Richmond, British Columbia-based company said it had a loss of 4 cents. The biotech drug developer posted revenue of $71,300 in the period. Its adjusted revenue was $71,000. For ...


Stock Market & Investing Books

Enter a stock symbol to view the stock details.